A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model

Journal of Infectious Diseases

Volumn 220, Issue 10, 2019, Pages 1558-1567

  Hashem, Anwar M ^a,b   Algaissi, Abdullah ^c,d   Agrawal, Anurodh Shankar ^c   Al Amri, Sawsan S ^b   Alhabbab, Rowa Y ^b   Sohrab, Sayed S ^b   Almasoud, Abdulrahman S ^e   Alharbi, Naif Khalaf ^e   Peng, Bi Hung ^c   Russell, Marsha ^f   Li, Xuguang ^f   Tseng, Chien Te K ^c,g  

^a King Abdulaziz University   (Saudi Arabia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c University of Texas Medical Branch School of Medicine   (United States)

^d JAZAN UNIVERSITY   (Saudi Arabia)

^e KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^f HEALTH CANADA   (Canada)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

adenovirus; CD40L; immunopathology; MERS CoV; vaccine

Indexed keywords

ADENOVIRUS VACCINE; CD40 LIGAND; IMMUNOGLOBULIN G; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS S1 SUBUNIT VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT ADENOVIRUS 5 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; CORONAVIRUS SPIKE GLYCOPROTEIN; DIPEPTIDYL PEPTIDASE IV; DRUG CARRIER; FUSION PROTEIN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CODON; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; LUNG HEMORRHAGE; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION; VIRUS LOAD; VIRUS TITRATION; ANIMAL; BLOOD; CORONAVIRUS INFECTION; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; LUNG; METABOLISM; SURVIVAL ANALYSIS; TRANSGENIC MOUSE; VIROLOGY;

ADENOVIRUSES, HUMAN; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD40 LIGAND; CORONAVIRUS INFECTIONS; DIPEPTIDYL PEPTIDASE 4; DRUG CARRIERS; GENETIC VECTORS; IMMUNOGLOBULIN G; LUNG; MICE; MICE, TRANSGENIC; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RECOMBINANT FUSION PROTEINS; SPIKE GLYCOPROTEIN, CORONAVIRUS; SURVIVAL ANALYSIS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL LOAD; VIRAL VACCINES;

EID: 85064499357     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiz137     Document Type: Article

References (50)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-20.
2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)-Saudi Arabia disease outbreak news, 26 January 2018. http://www. who. int/csr/don/26-january-2018-mers-saudi-arabia/en/. Accessed 29 October 2018.
3. Park SH, Kim YS, Jung Y, et al. Outbreaks of Middle East respiratory syndrome in two hospitals initiated by a single patient in Daejeon, South Korea. Infect Chemother 2016; 48:99-107.
4. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500:227-31.
5. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-4.
6. He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004; 324:773-81.
7. He Y, Li J, Du L, et al. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine 2006; 24:5498-508.
8. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV-A target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7:226-36.
9. Wang L, Shi W, Joyce MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 2015; 6:7712.
10. Coleman CM, Liu YV, Mu H, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014; 32:3169-74.
11. Al-Amri SS, Abbas AT, Siddiq LA, et al. Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci Rep 2017; 7:44875.
12. Ma C, Wang L, Tao X, et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptorbinding fragments-The importance of immunofocusing in subunit vaccine design. Vaccine 2014; 32:6170-6.
13. Song F, Fux R, Provacia LB, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 2013; 87:11950-4.
14. Guo X, Deng Y, Chen H, et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 2015; 145:476-84.
15. Haagmans BL, van den Brand JM, Raj VS, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 2016; 351:77-81.
16. Muthumani K, Falzarano D, Reuschel EL, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015; 7:301ra132.
17. Alharbi NK, Padron-Regalado E, Thompson CP, et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine 2017; 35:3780-8.
18. Zhou Y, Jiang S, Du L. Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines 2018; 17:677-86.
19. Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004; 78:12672-6.
20. Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012; 7:e35421.
21. Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A 2005; 102:797-801.
22. Czub M, Weingartl H, Czub S, He R, Cao J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 2005; 23:2273-9.
23. Deming D, Sheahan T, Heise M, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 2006; 3:e525.
24. Jaume M, Yip MS, Kam YW, et al. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med J 2012; 18(Suppl 2):31-6.
25. Olsen CW, Corapi WV, Ngichabe CK, Baines JD, Scott FW. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol 1992; 66:956-65.
26. Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 1981; 4:175-89.
27. He Y, Zhou Y, Wu H, et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 2004; 173:4050-7.
28. Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 2016; 12:2351-6.
29. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67:2-17.
30. Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 2009; 21:265-72.
31. Bishop GA, Hostager BS. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev 2003; 14:297-309.
32. Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993; 259:990-3.
33. Cao J, Wang X, Du Y, Li Y, Wang X, Jiang P. CD40 ligand expressed in adenovirus can improve the immunogenicity of the GP3 and GP5 of porcine reproductive and respiratory syndrome virus in swine. Vaccine 2010; 28:7514-22.
34. Gomez CE, Najera JL, Sanchez R, Jimenez V, Esteban M. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 2009; 27:3165-74.
35. Huang D, Pereboev AV, Korokhov N, et al. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Gene Ther 2008; 15:298-308.
36. Yao Q, Fischer KP, Li L, et al. Immunogenicity and protective efficacy of a DNA vaccine encoding a chimeric protein of avian influenza hemagglutinin subtype H5 fused to CD154 (CD40L) in Pekin ducks. Vaccine 2010; 28:8147-56.
37. Hashem AM, Gravel C, Chen Z, et al. CD40 ligand preferentially modulates immune response and enhances protection against influenza virus. J Immunol 2014; 193:722-34.
38. Fan X, Hashem AM, Chen Z, et al. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes. Mucosal Immunol 2015; 8:211-20.
39. Grehan K, Ferrara F, Temperton N. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX 2015; 2:379-84.
40. Tao X, Garron T, Agrawal AS, et al. Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2016; 90:57-67.
41. Kim E, Okada K, Kenniston T, et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014; 32:5975-82.
42. Munster VJ, Wells D, Lambe T, et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines 2017; 2:28.
43. Johnson TR, Parker RA, Johnson JE, Graham BS. IL-13 is sufficient for respiratory syncytial virus G glycoproteininduced eosinophilia after respiratory syncytial virus challenge. J Immunol 2003; 170:2037-45.
44. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21.
45. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34.
46. Tai W, Zhao G, Sun S, et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 2016; 499:375-82.
47. Volz A, Kupke A, Song F, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol 2015; 89:8651-6.
48. Malczyk AH, Kupke A, Prufer S, et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol 2015; 89:11654-67.
49. van Doremalen N, Hijazeen ZS, Holloway P, et al. High prevalence of Middle East respiratory coronavirus in young dromedary camels in Jordan. Vector Borne Zoonotic Dis 2017; 17:155-9.
50. Reusken CB, Haagmans BL, Muller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013; 13:859-66.